**Specifications table** {#s0005}
========================

TableSubject area*Biology*More specific subject area*Protein structure and biochemistry*Type of data*X-ray crystal structure, Mass spectrometry*How data was acquired*X-ray diffraction data were collected at Shanghai Synchrotron Radiation Facility. Mass spectra of MALDI-TOF-MS were obtained on a Bruker REFLEX III MALDI-TOF-MS (Bruker-Franzen, Bremen, Germany).*Data format*Processed*Experimental factors*Recombinant proteins were purified to high homogeneity before use.*Experimental features*The structure of the tPA*·*PAI-1 complex was determined by X-ray crystallography.*Data source location*City, Country and/or Latitude & Longitude (& GPS coordinates) for collected samples/data if applicable*Data accessibilityThe data is available from the related publication by Gong et al. [(http://www.ncbi.nlm.nih.gov/pubmed/26324706)](http://(www.ncbi.nlm.nih.gov/pubmed/26324706)){#ir0006}, and the structure deposited in the Protein Data Bank (entry 5BRR).

**Value of the data** {#s0010}
=====================

•Determines the crystal structure of the Michaëlis complex between tPA and PAI-1.•Provides insight on the specificity of PAI-1 for tPA and uPA.•Identifies key residues of tPA for binding to PAI-1.•Explains the PAI-1-resisting property of Tenecteplase.•Offers important clues to design newer generation of PAI-1-resistant tPA variants.

1. Data, experimental design, materials and methods {#s0015}
===================================================

1.1. Data and experimental design {#s0020}
---------------------------------

We have determined the structure of tPA·PAI-1 Michaëlis complex and identified key residues of tPA for binding to PAI-1 by X-ray crystallography, and the data are summarized in the original publication [@bib19].

We expressed the recombinant PAI-1 variant 14-1B (N150H, K154T, Q319L, and M354I) [@bib21], using the expression vector pT7-PL and BL21 cells as soluble protein [@bib22]. The choice of this particular variant is to obtain PAI-1 in active form, advantageous for crystallization, because the wild type PAI-1 has a half life of only 2 h and has propensity to spontaneously convert into an inactive, so-called latent form, and to aggregate at high concentration [@bib23], [@bib24].

PAI-1 inhibits tPA by a suicide-substrate mechanism common to all SERPIN members [@bib23], [@bib25] -- see [Fig. 1](#f0005){ref-type="fig"}A in the original publication [@bib19]. In this SERPIN mechanism, a long flexible loop of PAI-1 (reaction center loop, or RCL) inserts into the active site of tPA to form a transient Michaëlis complex. The RCL is cleaved by tPA through the classical serine proteolytic mechanism. tPA forms a covalent acyl-enzyme intermediate with PAI-1 by cleaving the scissible bond of PAI-1 RCL, following the Michaëlis complex. Before the hydrolysis of this acyl-enzyme intermediate, the PAI-1 RCL undergoes major conformational changes and inserts itself into the PAI-1 β-sheet A. At the same time, the tPA in the intermediate is pulled to the other side of PAI-1, distorted, and deactivated before the hydrolysis of the acyl-enzyme intermediate can take place.

Human tPA contains a fibronectin type II domain (amino acids 1--50), a growth factor domain (amino acids 51--91), two kringle domains (amino acids 92--261), an interdomain linker (amino acids 262--275) and a serine protease domain (SPD, amino acids 276--527) [@bib2] -- see [Fig. 1](#f0005){ref-type="fig"}B in the original publication [@bib19]. The tPA-SPD is the catalytic domain responsible for the plasminogen activation and is inhibited by PAI-1. Thus, we used only the recombinant tPA-SPD domain to form the Michaëlis complex with PAI-1. We generated three mutations in tPA-SPD: S478A (or S195A in the chymotrypsin numbering) to render the tPA-SPD catalytically inactive, so the Michaëlis complex does not proceed to a stable, covalent complex; N448Q (or N173Q in the chymotrypsin numbering) to remove the glycosylation on tPA-SPD, increasing the homogeneity of the recombinant protein and facilitating protein crystallization; and C395A (or C122A in the chymotrypsin numbering that will be used throughout the rest of text) mutation to remove the disulfide bond linked to K2 domain -- see [Fig. 1](#f0005){ref-type="fig"}B in the original publication [@bib19]. The recombinant tPA-SPD mutant was expressed in *P. pastoris* and confirmed by SDS-PAGE and mass spectrometry after trypsin digestion ([Table 1](#t0005){ref-type="table"}).

The recombinant PAI-1 14-1B and tPA-SPD were respectively dialysed into a high-concentration salt (1 M NaCl) and low pH (20 mM Mes pH 6.1) buffer before the Michaëlis complex formation. This condition is required to stabilize PAI-1 at its active form. Subsequently, these two proteins in high salt concentrations and low pH buffer were mixed in a 1:1 M ratio, followed by a dialysis into a low-concentration salt (150 mM NaCl) and neutral pH (20 mM Tris--HCl pH 7.4) buffer. This dialysing step ensures the complex formation similar to that in physiologic condition. A further gel filtration chromatography purification yielded a complex of greater than 99% purity.

2. Materials and methods {#s0025}
========================

2.1. Recombinant protein production {#s0030}
-----------------------------------

The recombinant PAI-1 mutant 14-1B [@bib21] containing four point mutations (N150H, K154T, Q319L, and M354I), and a hexa-His-tag was expressed in *E. coli*, using the expression vector pT7-PL and BL21 cells as previously described [@bib22]. The recombinant tPA-SPD was expressed in *P. pastoris* X-33. This strain facilitates the formation of five disulfide bonds (C42-C58, C50-C111, C100-C182, C136-C201, C168-C182 in chymotrypsin numbering) in tPA-SPD with a high yield about 50 mg recombinant protein per liter medium -- see in the original publication [@bib19].

2.2. The peptide mass fingerprinting of tPA-SPD by MALDI-TOF mass spectrometry {#s0035}
------------------------------------------------------------------------------

The SDS-PAGE was performed using 15% polyacrylamide gels. Following SDS-PAGE, the gels were stained with 0.1% (w/v) Coomassie brilliant blue R-250 in 25% (v/v) ethanol and 10% (v/v) acetic acid. The gel digestion was performed using a modified version of previously published protocol [@bib26]. Briefly, the gel band containing 100 ng tPA-SPD was excised from the 15% two-dimensional SDS-PAGE gel, cut in pieces, and destained by washing with 50% (v/v) acetonitrile in 100 μl of 25 mM NH~4~HCO~3~ for 30 min at room temperature. The gel pieces were then dried in a SpeedVac Vacuum (Savant Instruments, Holbrook, NY, USA) and rehydrated at 4 °C for 15 min in 3--5 μl digestion solution (25 mM NH~4~HCO~3~ and 12.5 ng/μl modified sequence-grade trypsin). Then 3--5 μl of digestion solution without trypsin was added to keep the gel pieces wet during the digestion. After overnight incubation at 37 °C, the digestion was stopped with 5% trifluoroacetic acid (TFA) for 20 min. The peptides were extracted by 20 μl of 5% TFA for 1 h at 37 °C and then by 20 μl of 2.5% TFA/50% acetonitrile for 1 h at 37 °C. The combined supernatants were evaporated in the SpeedVac Vacuum and dissolved in 4 μl 0.5% aqueous TFA for MS analysis.

All mass spectra of MALDI-TOF-MS were obtained on a Bruker REFLEX III MALDI-TOF-MS (Bruker--Franzen, Bremen, Germany) in positive ion mode at an accelerating voltage of 20 kV with the matrix of α-cyano-4-hydroxy cinnamic acid. The spectra were internally calibrated using trypsin autolysis products. The peptide mass fingerprinting obtained was used to search through the SWISS-PROT and NCBI database by the Mascot search engine [(http://mascot.proteomics.com.cn/)](http://(mascot.proteomics.com.cn/)){#ir0007} with a tolerance of \~+0.3 D and one missed cleavage site.

2.3. X-ray crystallography {#s0040}
--------------------------

The tPA-SPD·PAI-1 Michaëlis complex was formed by mixing tPA-SPD and PAI-1 in a 1:1 M ratio at low concentration (\~ 0.5 mg/ml), followed by dialysis into 20 mM Tris--HCl pH 7.4, and 150 mM NaCl, concentration to 0.5 ml volume for a further gel filtration chromatography purification, which yielded to a complex of greater than 99% purity. The purified complex was then concentrated to 10 mg/mL before setting up crystallization trials. Crystals of the tPA-SPD·PAI-1 Michaëlis complex were grown at 20 °C with the sitting drop method by mixing equal volumes of protein solution and precipitant solution (8% PEG-6000 and 0.1 M Tris pH 7.4), and appeared quickly within one day. However, the crystals always appeared as very thin plates, and decayed rapidly in the X-ray beam, posing great difficulty for X-ray data collection. Most crystals diffracted to only 4--5 Å at Shanghai Synchrotron Radiation Facility (SSRF) BL-17U beam line, and the diffracting spots often appeared as elongated or splitted shapes. After many crystallization and data collection trials for one and half years, one 3.16 Å data set was finally obtained at SSRF beam line BL17U using 25% glycerol as cryoprotectant at a wavelength of 0.979 Å. The data were processed and scaled using the HKL2000 program package [@bib27]. The crystal belongs to P2~1~2~1~2~1~ space group with one complex in the crystallographic asymmetric unit. The structure of the tPA-SPD·PAI-1 Michaëlis complex was solved by molecular replacement method using MolRep program [@bib28], which gave very strong and unambiguous solutions. A tPA-SPD molecule was first positioned inside the crystal lattice using the structure of the tPA-SPD catalytic domain (PDB code 1A5H) [@bib29] as a searching model and all the X-ray data up to 3.3 Å. The molecular replacement using MolRep gave a contrast of 12.33, a signal to sigma ratio for translational function of 16.02, and a correlation coefficient of 0.365. Next, the position of PAI-1 was searched using the model of active stable variant of PAI-1 (Protein Data Bank code 1DVM) [@bib30] while fixing the already positioned tPA-SPD model, giving only one translational function with a signal to sigma ratio of 19.4, and a correlation coefficient of 0.538. The molecular replacement model was subjected to iterative refinement and manual model rebuilding using Refmac [@bib31] and Coot [@bib32], respectively, giving a final R factor and R~free~ factor of 0.20 and 0.27, respectively. The structure was validated with PROCHECK [@bib33] and analyzed by PyMOL [@bib34] and PISA \[[@bib35]. The final refined crystal structure of tPA-SPD·PAI-1 Michaëlis complex was deposited in PDB with the code *5BRR*.

Appendix A. Supplementary material {#s0050}
==================================
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![A structural basis to design newer thrombolytics. Recombinant tPA (surface) is the FDA-approved thrombolytic drug. High dose of recombinant tPA is typically needed to lyse clot in stroke patients, partly due to its rapid inactivation by endogenous inhibitor (PAI-1, in ribbon). Such high dosage leads to dangerous side effects, including intracranial hemorrhage and neurotoxicity. Here, the crystal structure of tPA•PAI-1 Michaëlis complex was determined. This structure offers important clues to design newer generation of tPA thrombolytics with reduced PAI-1 inactivation.](gr1){#f0005}

###### 

Trypsin digested fragments of recombinant tPA-SPD SPD from MALDI-TOF-MS and the expected fragment mass.

Table 1.

  Mr observed (Da)   Mr calculated (Da)   Peptide sequence
  ------------------ -------------------- -----------------------
  1387.1             1386.8004            ^53^FPPHHLTVILGR^64^
  1335.8             1335.6328            ^142^HEALSPFYSER^152^
  1179.4             1179.6157            ^239^VTNYLDWIR^247^
  878.8              878.4618             ^231^DVPGVYTK^238^
  722.4              722.3831             ^160^LYPSSR^165^
